Amarin Highlights New REDUCE-IT Data at ESC 2026
DUBLIN and BRIDGEWATER, N.J., August 31, 2026 Amarin Corporation plc highlighted new findings from multiple REDUCE-IT® analyses presented at...
Myeloproliferative Neoplasms
Advertisement
PharmaEssentia Wins FDA Approval for BESREMi in ET
BURLINGTON, Mass., August 31, 2026 PharmaEssentia announced that the U.S. Food and Drug Administration (FDA) has approved BESREMi® (ropeginterferon...
Damora Therapeutics Initiates Phase 1/1b Trial of DMR-001
WALTHAM, Massachusetts, August 5, 2026 Damora Therapeutics, Inc. announced the initiation of the global Phase 1/1b CLARITY-101 clinical trial...
Damora Therapeutics Launches Phase 1 Trial of DMR-001
WALTHAM, Mass., Aug. 5, 2026 Damora Therapeutics, Inc. has announced the initiation of the global Phase 1/1b CLARITY-101 clinical...
Halozyme and Incyte Join Forces to Improve Cancer Drug Delivery
SAN DIEGO, July 20, 2026 Halozyme Therapeutics has entered into a global collaboration and license agreement with Incyte to...
Advertisements
SNIS 2026 Unveils AI Breakthrough in Brain Tumor Treatment
SEATTLE, July 20, 2026 The Society of NeuroInterventional Surgery (SNIS) has unveiled a series of groundbreaking scientific presentations for...
FDA Clears Dexcom Stelo OTC CGM for Children
SILVER SPRING, Maryland, June 12, 2026 The U.S. Food and Drug Administration (FDA) has cleared the Dexcom Stelo Glucose...
Menarini Reports Positive Phase 3 SENTRY Data at EHA
FLORENCE, Italy and NEW YORK, June 14, 2026 Menarini Group and its oncology-focused subsidiary Stemline Therapeutics have announced promising...
Karyopharm Highlights Phase 3 SENTRY Trial Progress in Myelofibrosis
NEWTON, Mass., June 1, 2026 Karyopharm Therapeutics has announced that it will host an investor conference call featuring leading...
Advertisement
